339 related articles for article (PubMed ID: 28132893)
21. Evaluation of the NRF1-proteasome axis as a therapeutic target in breast cancer.
Byers HA; Brooks AN; Vangala JR; Grible JM; Feygin A; Clevenger CV; Harrell JC; Radhakrishnan SK
Sci Rep; 2023 Sep; 13(1):15843. PubMed ID: 37739987
[TBL] [Abstract][Full Text] [Related]
22. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L; Kraus M; Besse A; Driessen C; Tarantino I
Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
[TBL] [Abstract][Full Text] [Related]
23. Structure-based design of human immuno- and constitutive proteasomes inhibitors.
Richy N; Sarraf D; Maréchal X; Janmamode N; Le Guével R; Genin E; Reboud-Ravaux M; Vidal J
Eur J Med Chem; 2018 Feb; 145():570-587. PubMed ID: 29339252
[TBL] [Abstract][Full Text] [Related]
24. Studies of C-terminal naphthoquinone dipeptides as 20S proteasome inhibitors.
Scotti A; Trapella C; Ferretti V; Gallerani E; Gavioli R; Marastoni M
J Enzyme Inhib Med Chem; 2016; 31(3):456-63. PubMed ID: 25942361
[TBL] [Abstract][Full Text] [Related]
25. Design, Synthesis, and Biological Activity of Isosyringolin A.
Kitahata S; Chiba T; Yoshida T; Ri M; Iida S; Matsuda A; Ichikawa S
Org Lett; 2016 May; 18(9):2312-5. PubMed ID: 27123978
[TBL] [Abstract][Full Text] [Related]
26. Proteasome inhibitors with pyrazole scaffolds from structure-based virtual screening.
Miller Z; Kim KS; Lee DM; Kasam V; Baek SE; Lee KH; Zhang YY; Ao L; Carmony K; Lee NR; Zhou S; Zhao Q; Jang Y; Jeong HY; Zhan CG; Lee W; Kim DE; Kim KB
J Med Chem; 2015 Feb; 58(4):2036-41. PubMed ID: 25658656
[TBL] [Abstract][Full Text] [Related]
27. Optimization of piperidine constructed peptidyl derivatives as proteasome inhibitors.
Zhao Y; Xu L; Zhang J; Zhang M; Lu J; He R; Xi J; Zhuang R; Li J; Zhou Y
Bioorg Med Chem; 2021 Jan; 29():115867. PubMed ID: 33223460
[TBL] [Abstract][Full Text] [Related]
28. Development of peptidomimetic boronates as proteasome inhibitors.
Micale N; Ettari R; Lavecchia A; Di Giovanni C; Scarbaci K; Troiano V; Grasso S; Novellino E; Schirmeister T; Zappalà M
Eur J Med Chem; 2013 Jun; 64():23-34. PubMed ID: 23639651
[TBL] [Abstract][Full Text] [Related]
29. Synthesis and antiproteasomal activity of novel O-benzyl salicylamide-based inhibitors built from leucine and phenylalanine.
Jorda R; Dušek J; Řezníčková E; Pauk K; Magar PP; Imramovský A; Kryštof V
Eur J Med Chem; 2017 Jul; 135():142-158. PubMed ID: 28441582
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and mechanistic studies of quinolin-chlorobenzothioate derivatives with proteasome inhibitory activity in pancreatic cancer cell lines.
Hu S; Jin Y; Liu Y; Ljungman M; Neamati N
Eur J Med Chem; 2018 Oct; 158():884-895. PubMed ID: 30253345
[TBL] [Abstract][Full Text] [Related]
31. p97-dependent retrotranslocation and proteolytic processing govern formation of active Nrf1 upon proteasome inhibition.
Radhakrishnan SK; den Besten W; Deshaies RJ
Elife; 2014; 3():e01856. PubMed ID: 24448410
[TBL] [Abstract][Full Text] [Related]
32. Proteasome inhibitors with photocontrolled activity.
Hansen MJ; Velema WA; de Bruin G; Overkleeft HS; Szymanski W; Feringa BL
Chembiochem; 2014 Sep; 15(14):2053-7. PubMed ID: 25125335
[TBL] [Abstract][Full Text] [Related]
33. Naphthoquinone amino acid derivatives, synthesis and biological activity as proteasome inhibitors.
Marastoni M; Trapella C; Scotti A; Fantinati A; Ferretti V; Marzola E; Eleonora G; Gavioli R; Preti D
J Enzyme Inhib Med Chem; 2017 Dec; 32(1):865-877. PubMed ID: 28657369
[TBL] [Abstract][Full Text] [Related]
34. Combination of Second-Generation Proteasome Inhibitor Carfilzomib with Bortezomib in Four Different Breast Cancer Cell Lines.
Altundag EM; Yilmaz AM; Sahin A; Yilmaz BK
Anticancer Agents Med Chem; 2022 Aug; 22(16):2909-2918. PubMed ID: 35352669
[TBL] [Abstract][Full Text] [Related]
35. Tradeoff between metabolic i-proteasome addiction and immune evasion in triple-negative breast cancer.
Adwal A; Kalita-de Croft P; Shakya R; Lim M; Kalaw E; Taege LD; McCart Reed AE; Lakhani SR; Callen DF; Saunus JM
Life Sci Alliance; 2020 Jul; 3(7):. PubMed ID: 32423906
[TBL] [Abstract][Full Text] [Related]
36. Proteasome inhibition correlates with intracellular bortezomib concentrations but not with antiproliferative effects after bolus treatment in myeloma cell lines.
Dettmer S; Theile D; Schäfer J; Seckinger A; Burhenne J; Weiss J
Naunyn Schmiedebergs Arch Pharmacol; 2016 Oct; 389(10):1091-101. PubMed ID: 27422413
[TBL] [Abstract][Full Text] [Related]
37. Anti-leukemic activity of bortezomib and carfilzomib on B-cell precursor ALL cell lines.
Takahashi K; Inukai T; Imamura T; Yano M; Tomoyasu C; Lucas DM; Nemoto A; Sato H; Huang M; Abe M; Kagami K; Shinohara T; Watanabe A; Somazu S; Oshiro H; Akahane K; Goi K; Kikuchi J; Furukawa Y; Goto H; Minegishi M; Iwamoto S; Sugita K
PLoS One; 2017; 12(12):e0188680. PubMed ID: 29236701
[TBL] [Abstract][Full Text] [Related]
38. Cisplatin Disrupts Proteasome Bounce-Back Effect through Suppressing ZEB1/Nfe2l1 in Cholangiocarcinoma.
Xiang Y; Jia M; Gao Y; Yang F; Wang T; Dai R; Wang M; Miao H
Front Biosci (Landmark Ed); 2024 Mar; 29(3):106. PubMed ID: 38538281
[TBL] [Abstract][Full Text] [Related]
39. Exploring the Binding Affinity of Novel Syringic Acid Analogues and Critical Determinants of Selectivity as Potent Proteasome Inhibitors.
Cheemanapalli S; Anuradha CM; Madhusudhana P; Mahesh M; Raghavendra PB; Kumar CS
Anticancer Agents Med Chem; 2016; 16(11):1496-1510. PubMed ID: 27173965
[TBL] [Abstract][Full Text] [Related]
40. High-dose carfilzomib achieves superior anti-tumor activity over low-dose and recaptures response in relapsed/refractory multiple myeloma resistant to lowdose carfilzomib by co-inhibiting the β2 and β1 subunits of the proteasome complex.
Zhou X; Besse A; Peter J; Steinhardt MJ; Vogt C; Nerreter S; Teufel E; Stanojkovska E; Xiao X; Hornburger H; Haertle L; Lopez MM; Munawar U; Riedel A; Han S; Maurits E; Overkleeft HS; Florea B; Einsele H; Kortüm KM; Driessen C; Besse L; Rasche L
Haematologica; 2023 Jun; 108(6):1628-1639. PubMed ID: 36727403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
